FDA Clinical Pharmagenomics
Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Biosimilars Basic principles of clinical development Gonzalo Calvo Hospìtal Clínic de Barcelona European Association for Clinical Pharmacology and Therapeutcis.
Bartnikas - Partial Discharges Their Mechanism, Detection and Measurement - 2002
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Parkinson's Disease Katherine Patetta March 6, 2013 Period 1.
